S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
High short interest stocks: this popular trend is re-emerging
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
High short interest stocks: this popular trend is re-emerging
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
High short interest stocks: this popular trend is re-emerging
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
High short interest stocks: this popular trend is re-emerging
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it

Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.01
▼
$0.13
52-Week Range
N/A
Volume
2.48 million shs
Average Volume
2.58 million shs
Market Capitalization
$726,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media

INFI stock logo

About Infinity Pharmaceuticals Stock (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.


INFI Stock News Headlines

December 1, 2023 | seekingalpha.com
INFIQ Infinity Pharmaceuticals, Inc.
October 16, 2023 | businesswire.com
INFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities ...
December 11, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 16, 2023 | barrons.com
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
October 15, 2023 | stockhouse.com
Infinity Ongoing Deadline Alert
October 14, 2023 | bloomberg.com
Deadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have Opportuni
October 10, 2023 | finance.yahoo.com
Infinity Pharmaceuticals, Inc. (INFIQ)
October 9, 2023 | barrons.com
Bronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!
December 11, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
October 2, 2023 | bizjournals.com
Gutted Cambridge biotech declares bankruptcy after failed merger, layoffs
October 1, 2023 | markets.businessinsider.com
Infinity Investor Shareholder Alert
September 29, 2023 | msn.com
Infinity Pharmaceuticals reportedly files for Chapter 11
September 22, 2023 | finanznachrichten.de
Faron Pharmaceuticals Oy: Faron Pharmaceuticals Announces Board Changes
September 18, 2023 | stockhouse.com
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 16, 2023 | prnewswire.com
INFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options
September 16, 2023 | markets.businessinsider.com
ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
September 15, 2023 | stockhouse.com
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 14, 2023 | stockhouse.com
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 13, 2023 | gurufocus.com
Director Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)
September 13, 2023 | stockhouse.com
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 13, 2023 | seekingalpha.com
Infinity Pharmaceuticals receives delisting determination letter from Nasdaq
September 11, 2023 | stockhouse.com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 6, 2023 | benzinga.com
INFI Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Infinity Pharmaceuticals, Inc.
September 6, 2023 | stockhouse.com
Infinity Shareholder Notice
September 6, 2023 | finanznachrichten.de
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 5, 2023 | finance.yahoo.com
Three execs leave Infinity Pharmaceuticals after failed merger, layoffs
September 2, 2023 | stockhouse.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
See More Headlines
Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
12/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INFI
CUSIP
45665G30
CIK
1113148
Web
www.infi.com
Phone
(617) 453-1000
Fax
617-453-1001
Employees
30
Year Founded
2000

Profitability

EPS (Most Recent Fiscal Year)
($0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-44,370,000.00
Net Margins
-1,593.93%
Pretax Margin
-1,593.93%
Return on Equity
N/A
Return on Assets
-113.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.65
Quick Ratio
1.65

Sales & Book Value

Annual Sales
$2.59 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.21) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
90,760,000
Free Float
81,857,000
Market Cap
$726,000.00
Optionable
Optionable
Beta
1.63

Social Links

The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Lawrence E. Bloch J.D. (Age 57)
    M.D., Treasurer
    Comp: $513.61k
  • Mr. Seth A. Tasker J.D. (Age 44)
    CEO, Sr. VP, Gen. Counsel & Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions














INFI Stock Analysis - Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings or view top-rated stocks.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The biotechnology company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.45 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share.

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il.
View institutional ownership trends.

This page (NASDAQ:INFI) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -